Edition:
United Kingdom

Ardelyx Inc (ARDX.OQ)

ARDX.OQ on NASDAQ Stock Exchange Global Market

7.30USD
19 Jan 2018
Change (% chg)

$0.20 (+2.82%)
Prev Close
$7.10
Open
$7.10
Day's High
$7.40
Day's Low
$7.05
Volume
63,192
Avg. Vol
141,823
52-wk High
$15.40
52-wk Low
$4.05

Chart for

About

Ardelyx, Inc. is a clinical-stage biopharmaceutical company. The Company's therapeutics focuses on addressing cardiorenal and gastrointestinal (GI) diseases. It operates through the research, development and commercialization of biopharmaceutical products segment. The Company's products line includes cardiorenal portfolio and... (more)

Overall

Beta: 0.24
Market Cap(Mil.): $268.07
Shares Outstanding(Mil.): 47.45
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 85.70 16.58
EPS (TTM): -- -- --
ROI: -- 3.19 10.60
ROE: -- 4.52 14.19

BRIEF-Ardelyx Says Co Had About $134 Million In Cash

* ARDELYX SAYS ON JAN 8, CO HAD ABOUT $134 MILLION IN CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS AS OF DEC 31, 2017 Source text: (http://bit.ly/2AETXHu) Further company coverage:

08 Jan 2018

BRIEF-Ardelyx Successfully Completes T3mpo-3 Safety Extension Study Of Tenapanor For Ibs-C

* ARDELYX SUCCESSFULLY COMPLETES T3MPO-3 SAFETY EXTENSION STUDY OF TENAPANOR FOR IBS-C

03 Jan 2018

BRIEF-Ardelyx announces license agreement with Shanghai Fosun Pharmaceutical Industrial Development Co for Tenapanor in China

* Ardelyx announces license agreement with Shanghai Fosun Pharmaceutical Industrial Development Company Limited for Tenapanor in China

11 Dec 2017

BRIEF-Ardelyx Inc says has decided to discontinue development of RDX7675 for treatment of hyperkalemia​​

* Ardelyx announces updated development path for its cardiorenal pipeline

21 Nov 2017

BRIEF-Ardelyx qtrly ‍net loss per common share $0.44​

* Ardelyx reports third quarter 2017 operating results and clinical progress

07 Nov 2017

BRIEF-Rock Springs Capital Management reports 5.02 pct passive stake in Ardelyx - SEC Filing

* Rock Springs Capital Management LP​ reports 5.02 percent passive stake in Ardelyx Inc as of Oct 23 - SEC filing Source text : (http://bit.ly/2gXpxsM) Further company coverage:

02 Nov 2017

Ardelyx's constipation drug succeeds in late-stage trial

Ardelyx Inc said a second late-stage trial of its drug for irritable bowel syndrome with constipation (IBS-C) met the main goal of reducing abdominal pain and increasing bowel movement, sending its shares up sharply in extended trading.

11 Oct 2017

BRIEF-Ardelyx's Phase 3 study of Tenapanor for IBS-C hits primary and secondary endpoints

* Ardelyx's pivotal Phase 3 study of Tenapanor for IBS-C hits primary and all secondary endpoints to support NDA submission in 2018

11 Oct 2017

Ardelyx's irritable bowel syndrome drug succeeds in trial

Oct 11 Ardelyx Inc said on Wednesday a second late-stage trial of its experimental drug for irritable bowel syndrome with constipation (IBS-C) met the main goal of reducing abdominal pain and increasing bowel movements.

11 Oct 2017

BRIEF-Deerfield Management reports a 5.79 pct passive stake in Ardelyx‍​

* Deerfield Management LP reports a 5.79 pct passive stake in Ardelyx Inc as of August 21 - SEC filing ‍​ Source text: (http://bit.ly/2vMywBL) Further company coverage:

31 Aug 2017

Earnings vs. Estimates